<div id="readability-page-1"><div><h2>Conference spotlight and mixed analyst signals</h2> <p>DexCom (DXCM) is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, an event drawing extra attention after a recent mix of analyst rating changes.</p> <p>For you as an investor, that combination of a high profile conference appearance and differing analyst views creates an opportunity to reassess how DexCom’s current share price relates to its continuous glucose monitoring business.</p> <p>See our latest analysis for DexCom.</p> <p>Recent trading has been relatively steady, with DexCom’s 90 day share price return of 3.37% and 1 year total shareholder return of a 13.32% decline suggesting momentum has been muted even as conference expectations and mixed analyst commentary shape sentiment around growth and risk.</p> <p>With DexCom in focus this week, it could be a useful moment to see how other medical names are shaping up too, using healthcare stocks as a starting list of ideas.</p> <p>So with DexCom shares down 13.32% over the past year, trading around $67.40 against an average analyst target of $85.35, is this a genuine entry point, or are markets already baking in the next leg of growth?</p> <h2>Most Popular Narrative: 21% Undervalued</h2> <p>With DexCom last closing at $67.40 against a narrative fair value of about $85.27, the current price sits well below that modeled estimate.</p> <blockquote> <p><em>Analysts are assuming DexCom's revenue will grow by 14.8% annually over the next 3 years.</em></p> <p><em>Analysts assume that profit margins will increase from 13.3% today to 21.9% in 3 years time.</em></p> </blockquote> <p>Read the complete narrative.</p> <p>Curious how that gap between the share price and fair value is justified? Revenue expansion, margin lift, and a richer future earnings multiple are all central to this narrative.</p> <p><strong>Result: Fair Value of $85 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, this hinges on assumptions that could easily be challenged if Medicare competitive bidding pressures pricing, or if legal and product quality headlines drag on sentiment.</p> <p>Find out about the key risks to this DexCom narrative.</p> <h2>Another View: Cash Flows Point to a Richer Price</h2> <p>The fair value narrative suggests DexCom is undervalued around $67, but our DCF model tells a different story. On those cash flow assumptions, estimated fair value sits closer to $53.26, which implies the shares look expensive. Is the market leaning too hard into the growth story?</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5d9c0465-21d1-4299-acb4-e223ed4cfe11/chart/dcf?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5d9c0465-21d1-4299-acb4-e223ed4cfe11/chart/dcf"/><figcaption>DXCM Discounted Cash Flow as at Jan 2026</figcaption></figure><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out DexCom for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 882 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2> Build Your Own DexCom Narrative</h2> <p>If you are not sold on these assumptions or simply want to stress test the numbers yourself, you can build a fresh view in minutes with Do it your way.</p> <p>A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding DexCom.</p> <h2>Looking for more investment ideas?</h2> <p>If DexCom has you thinking harder about risk and reward, do not stop here. Broaden your watchlist with a few targeted stock ideas that fit your style.</p> <ul> <li>Spot potential high flyers early by scanning these 3539 penny stocks with strong financials for smaller names that already show solid financial footing.</li> <li>Zero in on strong cash generators with these 882 undervalued stocks based on cash flows and see which companies trade at prices that differ from their cash flow potential.</li> <li>Tap into long term income themes through these 12 dividend stocks with yields &gt; 3% if you want companies that prioritize returning cash to shareholders.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

DXCM

<p>DexCom (DXCM) will present at the J.P. Morgan Healthcare Conference on January 12, amid mixed analyst ratings. Currently trading at $67.40, below the average target of $85.35, analysts project a 14.8% annual revenue growth and margin increase to 21.9% in three years. However, a discounted cash flow model suggests a fair value of $53.26, indicating shares may be overvalued. Investors are encouraged to assess risks and explore additional investment opportunities in healthcare stocks.</p>

Assessing DexCom (DXCM) Valuation As Analyst Actions And Conference Spotlight Shape Sentiment